Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone scan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,307 result(s) found for: Bone scan. Displaying page 9 of 66.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2017-003549-72 Sponsor Protocol Number: SMR-3165 Start Date*: 2017-12-22
    Sponsor Name:Oncology Venture Aps
    Full Title: Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood ...
    Medical condition: AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010726-19 Sponsor Protocol Number: 20080562 Start Date*: 2009-08-20
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) IT (Completed) ES (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004210-10 Sponsor Protocol Number: ASSTBS-BLADE-2540-2016 Start Date*: 2017-03-29
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A PILOT PHASE IV STUDY TO EVALUATE VARIATION IN BONE MINERAL DENSITY, LEAN AND FAT BODY MASS MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH PROSTATE CANCER WITHOUT BONE METASTASIS T...
    Medical condition: prostate cancer prostate cancer without bone metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000782-22 Sponsor Protocol Number: SAHA-Pilot-2016 Start Date*: 2017-01-03
    Sponsor Name:Medical University of Graz
    Full Title: A pilot study of peroral Vorinostat (Zolinza) in patients with refractory histone deacetylase-positive uterine sarcoma.
    Medical condition: Uterine sarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024665-52 Sponsor Protocol Number: AMSC-DSD-001 Start Date*: 2013-07-24
    Sponsor Name:Bioinova, s.r.o.
    Full Title: Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy.
    Medical condition: Spinal degenerative disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10070241 Degenerative disc disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002767-26 Sponsor Protocol Number: LyRICX Start Date*: 2019-06-25
    Sponsor Name:Academic Medical Center
    Full Title: Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)
    Medical condition: gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004116-22 Sponsor Protocol Number: MK-3475-921 Start Date*: 2019-04-29
    Sponsor Name:Merck Sharp & Dohme LCC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003093-48 Sponsor Protocol Number: 21140 Start Date*: 2021-04-29
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prost...
    Medical condition: Metastatic hormone-sensitive prostate cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005684-32 Sponsor Protocol Number: Start Date*: 2015-12-30
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: [18F] DIHYDRO-TESTOSTERONE PET IMAGING IN PATIENTS WITH PROGRESSIVE PROSTATE CANCER
    Medical condition: Progressive Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004564-32 Sponsor Protocol Number: NG 05 / 09 Start Date*: 2007-03-06
    Sponsor Name:University Medical center Utrecht
    Full Title: The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and...
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004735-32 Sponsor Protocol Number: SP001 Start Date*: 2012-01-11
    Sponsor Name:SOTIO a.s.
    Full Title: Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with castrate-resistant prostate cancer
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-011888-37 Sponsor Protocol Number: CZOL446HDE40 Start Date*: 2010-07-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multip...
    Medical condition: osteoporosis in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004391-35 Sponsor Protocol Number: NSABP-FB7 Start Date*: 2014-02-18
    Sponsor Name:Puma Biotechnology Inc.
    Full Title: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosp...
    Medical condition: Locally advanced HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000159-15 Sponsor Protocol Number: PRTK15-TL/SONCHIMIO Start Date*: 2018-01-12
    Sponsor Name:CHRU TOURS
    Full Title: Targeted delivery of chemotherapy with ultrasound and microbubbles
    Medical condition: Colo-Rectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021868-15 Sponsor Protocol Number: 9785-CL-0222 Start Date*: 2011-07-25
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004850-97 Sponsor Protocol Number: 13-21 Start Date*: 2014-07-11
    Sponsor Name:Cancer Trials Ireland
    Full Title: A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000849-19 Sponsor Protocol Number: 20050234 Start Date*: 2006-10-27
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density
    Medical condition: Postmenopausal Osteoporosis/osteopenia
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004825-26 Sponsor Protocol Number: G200712 Start Date*: 2013-01-25
    Sponsor Name:GTx, Inc.
    Full Title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on and...
    Medical condition: Assessments of serum total testosterone, serum free testosterone, serum SHGB and serum PSA concentrations will be made. Bone turnover markers and the incidence and frequency of hot flashes will be ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003847-66 Sponsor Protocol Number: H6Q-MC-S061 Start Date*: 2008-03-28
    Sponsor Name:Eli Lilly and company
    Full Title: Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Medical condition: Renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001487-19 Sponsor Protocol Number: 35/14 Start Date*: 2016-04-07
    Sponsor Name:Swiss Group For Clinical Cancer Research (SAKK)
    Full Title: Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy.
    Medical condition: Follicular Lymphoma (FL), advanced disease in need of therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Prematurely Ended) SE (Ongoing) FI (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:15:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA